Compare KTTA & REFR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KTTA | REFR |
|---|---|---|
| Founded | 2020 | 1965 |
| Country | United States | United States |
| Employees | 5 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Multi-Sector Companies |
| Sector | Health Care | Miscellaneous |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.2M | 20.9M |
| IPO Year | N/A | 1995 |
| Metric | KTTA | REFR |
|---|---|---|
| Price | $0.54 | $0.48 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | ★ 436.1K | 30.4K |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,488,642.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.28 | $0.55 |
| 52 Week High | $2.06 | $2.70 |
| Indicator | KTTA | REFR |
|---|---|---|
| Relative Strength Index (RSI) | 35.96 | 19.83 |
| Support Level | $0.49 | N/A |
| Resistance Level | $0.76 | $0.83 |
| Average True Range (ATR) | 0.05 | 0.06 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 37.62 | 2.83 |
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company has reportable segment, which is the business of research and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers.
Research Frontiers Inc is engaged in the development and marketing of technology and devices to control the flow of light. The company develops and licenses its patented suspended particle device light-control technology to other companies that manufacture and market the SPD-Smart chemical emulsion, the light-control film made from the chemical emulsion, the light-control panels made by laminating the film, electronics to power end-products incorporating the film, or lamination services for, and the end-products. The company's revenue source comes from the licensing of technology.